peptech announces resolution to abbott dispute

Peptech announces resolution to Abbott dispute
Australian biotechnology company, Peptech Limited has reached an agreement in
principle to resolve its recent dispute with Abbott Laboratories over its license
arrangements for sales of HUMIRA®, a treatment for rheumatoid arthritis (RA). The
confidential resolution is expected to be finalised in the coming weeks and is subject
to final approval by both companies.
Peptech Executive Chairman, Mr. Mel Bridges said he was delighted that a
satisfactory business resolution to the patent dispute had been reached with the
healthcare company.
"With this dispute resolved, Peptech can refocus its strategy and now take advantage
of a number of market opportunities," Mr. Bridges said.